Author:
Karam A.,Ledermann J.A.,Kim J.-W.,Sehouli J.,Lu K.,Gourley C.,Katsumata N.,Burger R.A.,Nam B.-H.,Bacon M.,Ng C.,Pfisterer J.,Bekkers R.L.M.,Casado Herráez A.,Redondo A.,Fujiwara H.,Gleeson N.,Rosengarten O.,Scambia G.,Zhu J.,Okamoto A.,Stuart G.,Ochiai K.
Funder
Astra Zeneca UK Limited
Bristol-Myers Squibb Company
Clovis Oncology Inc.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Pharma Mar, S.A.
TESARO, Inc.
Zeria Pharmaceutical Co., Ltd.
Reference47 articles.
1. First-Line Therapy in Ovarian Cancer Trials;Thigpen;Int J Gynecol Cancer,2011
2. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review;du Bois;Gynecol Oncol,2009
3. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010
4. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015
5. Optimal primary surgical treatment for advanced epithelial ovarian cancer;Elattar,1996